Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
Status:
Not yet recruiting
Trial end date:
2027-03-30
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of Pembrolizumab in combination
with Bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small cell lung
cancer (NSCLC) with EGFR exon 20 insertion mutation.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Chest Hospital
Collaborator:
Merck Sharp & Dohme LLC
Treatments:
Bevacizumab Carboplatin Dexamethasone Folic Acid Pembrolizumab Pemetrexed Vitamin B 12